Medications for the treatment of pulmonary arterial hypertension: a systematic review and network meta-analysis

Лекарственные препараты для лечения легочной артериальной гипертензии: систематический обзор и сетевой метаанализ
Shaneela Shahid, Dena Zeraatkar, Pakeezah Saadat, Lisa Marie Mielniczuk, Sanjay Mehta, Tyler Pitre, Johnny S. Su, Sonya Cui, Ryan Scanlan, Christopher Chiang, Renata Husnudinov, Muhammad Faran Khalid, Nadia Khan, Gareth Leung, David Mikhail, Jasmine Cassy Mah
2022-08-10

endothelin receptor antagonistsnetwork meta-analysisphosphodiesterase-5 inhibitorspulmonary arterial hypertensionriociguat
BACKGROUND: There is no consensus on the most effective treatments of pulmonary arterial hypertension (PAH). Our objective was to compare effects of medications for PAH. METHODS: We searched MEDLINE, Embase, the Cochrane Central Register of Controlled Trials and Clinicaltrials.gov from inception to December 2021. We performed a frequentist random-effects network meta-analysis on all included trials. We rated the certainty of the evidence using the Grades of Recommendation, Assessment, Development, and Evaluation approach. RESULTS: We included 53 randomised controlled trials with 10 670 patients. Combination therapy with endothelin receptor antagonist (ERA) plus phosphodiesterase-5 inhibitors (PDE5i) reduced clinical worsening (120.7 fewer events per 1000, 95% CI 136.8-93.4 fewer; high certainty) and was superior to either ERA or PDE5i alone, both of which reduced clinical worsening, as did riociguat monotherapy (all high certainty). PDE5i (24.9 fewer deaths per 1000, 95% CI 35.2 fewer to 2.1 more); intravenous/subcutaneous prostanoids (18.3 fewer deaths per 1000, 95% CI 28.6 fewer deaths to 0) and riociguat (29.1 fewer deaths per 1000, 95% CI 38.6 fewer to 8.7 more) probably reduce mortality as compared to placebo (all moderate certainty). Combination therapy with ERA+PDE5i (49.9 m, 95% CI 25.9-73.8 m) and riociguat (49.5 m, 95% CI 17.3-81.7 m) probably increase 6-min walk distance as compared to placebo (moderate certainty). CONCLUSION: Current PAH treatments improve clinically important outcomes, although the degree and certainty of benefit vary between treatments.
1
A systematic review and network meta-analysis included 53 randomized controlled trials involving 10,670 patients with pulmonary arterial hypertension.
2
Combination therapy with an endothelin receptor antagonist plus a phosphodiesterase-5 inhibitor substantially reduced clinical worsening and was superior to either monotherapy.
3
Endothelin receptor antagonist plus phosphodiesterase-5 inhibitor therapy and riociguat probably improved 6-minute walk distance by approximately 50 meters versus placebo.
4
Endothelin receptor antagonists, phosphodiesterase-5 inhibitors, and riociguat monotherapy each reduced clinical worsening compared with placebo, with high-certainty evidence.
5
Phosphodiesterase-5 inhibitors, intravenous or subcutaneous prostanoids, and riociguat probably reduce mortality compared with placebo, although evidence certainty was moderate.

Medications for pulmonary arterial hypertension

Comparative effects on clinical worsening, mortality, and 6-minute walk distance

Publication Details
Publication Date
2022-08-10
Journal
Publisher
ISSN
Cited by
32
Access Type
Author Information
Authors
Shaneela Shahid
Dena Zeraatkar
Pakeezah Saadat
Lisa Marie Mielniczuk
Sanjay Mehta
Tyler Pitre
Johnny S. Su
Sonya Cui
Ryan Scanlan
Christopher Chiang
Renata Husnudinov
Muhammad Faran Khalid
Nadia Khan
Gareth Leung
David Mikhail
Jasmine Cassy Mah
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%